{"name":"AxeroVision, Inc.","slug":"axerovision-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AXR-159","genericName":"AXR-159","slug":"axr-159","indication":"Other","status":"phase_2"},{"name":"AXR-270 High Dose","genericName":"AXR-270 High Dose","slug":"axr-270-high-dose","indication":"Other","status":"phase_2"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"AXR-270 Low Dose","genericName":"AXR-270 Low Dose","slug":"axr-270-low-dose","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"AXR-159","genericName":"AXR-159","slug":"axr-159","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AXR-270 High Dose","genericName":"AXR-270 High Dose","slug":"axr-270-high-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AXR-270 Low Dose","genericName":"AXR-270 Low Dose","slug":"axr-270-low-dose","phase":"phase_2","mechanism":"AXR-270 Low Dose is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxPNENwZFNOUy00TGpWSmJHbWV1V2UwQU5QWjAyd2owSUdlcWV2aThqZDktLXdJLVJubmVIMFQtal8zRlgxTEY2T1U0eWFYU2d3enMwMXdYaHN4NjZKSGxOTTRTdzRXX2tFVzZOSlFLYW5ZOTE2Y1FIcXB5dFhFd2ZfdS1jdDRXVUpvTG1mUjZrYk9tcFIzbGl3YWVWZV90T3EwZ1pSeEVRdWhVT0dOb1JMZnMzMGJ1VVhWeUVxdG1hRGVia04zNnZGVTRKQUUxU3FRN0dFRGtHejlKRnJmMEx4R2x5Xzc1QVAyNS16R1A3WkFxR1VvZHdyUTREWnJYa2h2cUJlUVVmN29XMFVxZWk0MEtUdTlSWGs3Y0VNdnNCMXNCOUlieDZyTHgtX2FpYnJBN1E?oc=5","date":"2025-07-14","type":"pipeline","source":"PR Newswire","summary":"MCR Therapies Market Set to Grow Rapidly Across the 7MM During the Forecast Period (2020-2034) with New Indications and Pipeline Advancements | DelveInsight - PR Newswire","headline":"MCR Therapies Market Set to Grow Rapidly Across the 7MM During the Forecast Period (2020-2034) with New Indications and ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNUTlueFcxMloxdHhmMklNRmVicU9oc1hZMkY1dElEeUNUeWJTdmV2YzJycktUNG1STmthZ1FOLXBweTM4WTZCZVF4TXc3VHVXS01rdUhfMXVUZmp4N3VBQUR5RkI2M2Q3b1pGaGNzeG5OZDF1YmdHWFZVQkkyMS1HTV9zMG96WEluMk12MU5XaEVWWHhhZXpmZ19Fd2pSelNuN0FoVXozMERsVHd0YnJVdlYyb1d1LTNJU1NQdWItM3hxZ3RlZ01mcw?oc=5","date":"2025-01-28","type":"pipeline","source":"PR Newswire","summary":"Dry Eye Disease Market to Observe Stupendous Growth by 2034 | DelveInsight - PR Newswire","headline":"Dry Eye Disease Market to Observe Stupendous Growth by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxORUlqZFV6ZFNoMzRSb0h3SU9rdzRNalY1ZEhpNjZIVl9haHVNTDg4VlRqRnU0OG1GYlQ5cUdOV1lnLTF1V3pobng3U1pZLW5DMENIUkdmTVBHSDB3UVJOc2t6MHZ5ZFdsNjhZVndYM1RoZ2Y1em5vYTVXMExmZGRRaC1uU2tWWXRyYTlKVWVjSWw2ZHBPdzF6UlhaRTh0RGZiVl94WVdiYkpOVzJESnZNMkRjOEp4QWlrQy1fTHluZlBtQkVZT3g4d2hiV2pkeklBMFYtaHllQS1OQ0c1QWNsc3lGMlVPWVBpQ0hxU2JWVlRpMkRV?oc=5","date":"2021-08-31","type":"trial","source":"PR Newswire","summary":"AxeroVision, Inc. Announces Phase 2 Results for AXR-270 for Treatment of Dry Eye Disease Associated With MGD - PR Newswire","headline":"AxeroVision, Inc. Announces Phase 2 Results for AXR-270 for Treatment of Dry Eye Disease Associated With MGD","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":3},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}